Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii

Clinical Toxicology

Volumn 45, Issue 5, 2007, Pages 549-556

  Brown, Amy C ^a,b   Onopa, Janet ^a,b,d   Holck, Peter ^a,b   Kaufusi, Pakieli ^a,b   Kabasawa, Derek ^b   Craig, Winston J ^c   Dragull, Klaus ^b,d   Levine, Arieh M ^b,d   Baker, Jonathan D ^b,d  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c ANDREWS UNIVERSITY   (United States)

^d Andrews University ^*  (United States)

Author keywords

Beverage; Hepatotoxicity; Kava; Liver function test; Pacific Islanders

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; KAVA; PROTEIN;

ADULT; ARTICLE; BEVERAGE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMOCHROMATOSIS; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; SCREENING; UNITED STATES; VIRUS HEPATITIS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BEVERAGES; BILIRUBIN; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAWAII; HUMANS; KAVA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; PLANT EXTRACTS;

PIPER METHYSTICUM;

EID: 34248545938     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701365875     Document Type: Article

References (31)

1. Singh YN. Kava: An overview. J Ethnopharmacol 1992; 37(1):13-45.
2. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005; 19(3):183-188.
3. Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie J. Saccade and cognitive function in chronic kava users. Neuropsychopharmacology 2003; 28(2):389-396.
4. Nerurkar PV, Dragull K, Tang CS. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells as compared to kavalactones. Toxicol Sci 2004; 79(1):106-111.
5. Hu L, Jhoo JW, Ang CY, Dinovi M, Mattia A. Determination of six kavalactones in dietary supplements and selected functional foods containing Piper methysticum by isocratic liquid chromatography with internal standard. J AOAC Int 2005; 88(1):16-25.
6. Bobeldigjk I, Boonzaaijer G, Spies-Faber EJ, Vaes WH. Determination of kava lactones in food supplements by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr A 2005; 1067(1-2):107-114.
7. Clough AR, Jacups SP, Wang Z, Burns CB, Bailie RS, Cairney SJ, Collie A, Guyula T, McDonald SP, Currie BJ. Health effects of kava use in an eastern Arnhem Land Aboriginal community. Int Med J 2003; 33(8):336-340.
8. Perez J, Holmes JF. Altered mental status and ataxia secondary to acute kava ingestion. J Emerg Med 2005; 28(1):49-51.
9. Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJ. Saccade and cognitive impairment associated with kava intoxication. Human Psychopharmacology 2003; 18(7):525-533.
10. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; (1):CD003383.
11. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol 2004; 93(2-3):153-160.
12. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exper Pharm Phys 1990; 17(7):509-514.
13. Almeida JC, Grimsely EW. Coma from the health food store: Interaction between kava and alprazolam. Ann Int Med 1996; 125(11):940-941.
14. Wooltorton E. Herbal kava: reports of liver toxicity. CMAJ 2002; 166(6):777.
15. Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent S. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf 2005; 4:779-794.
16. Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett 2004; 150(1):85-96.
17. Mathews JD, Riley MD, Fejo L, Munoz E, Munos E, Milns NR, Gardner ID, Powers JR, Ganygulpa E, Gununuwawuy BJ. Effects of the heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148:548-555.
18. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 2003; 15:1033-1036.
19. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003; 41(6):821-829.
20. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2005. 〈http://www.R-project.org〉
21. Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, Domschke W, Lerch MM. Fulminant liver failure after administration of the herbal antidepressant kava-kava. Dtsch Med Wochenschr 2001; 126(36):970-972.
22. Siest G, Batt AM, Fournel-Gigleux S, Galteau MM, Wellman-Bednawska M, Minn A, Costesec AA. Induction of plasma and tissue enzymes by drugs: Significance in toxicological studies. Xenobiotica 1988; 18(suppl 1):21-34.
23. Jhoo JW, Freeman JP, Heinze TM, Moody JD, Schnackenberg LK, Beger RD, Dragull K, Tang CS, Ang CY. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J Agric Food Chem 2006; 54(8):3157-3162.
24. Currie BJ, Clough AR. Kava hepatotoxicity with western herbal products: Does it occur with traditional kava use? Med J Aust 2003; 178(9):421-422.
25. Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 2003; 39:62-67.
26. Mathews JM, Etherridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002; 30:1153-1157.
27. Gurley JB, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Han IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77(5):415-426.
28. Russmann S, Barguil Y, Cabalion P, Rentsch K. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: Protective effect against environmental carcinogens? Clin Pharmacol Thera 2005; 77(5):453-454.
29. Russmann S, Helbling A. Kava hepatoxicity. Ann Int Med 2001; 135(1):68-69.
30. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352(17):1769-78.
31. Teschke R. Kava, kavapyrones and toxic liver injury. Z Gastroenterol 2003; 41(5):395-404.